Cara Therapeutics Inc. (CARA)
5.15
-0.19 (-3.56%)
At close: Mar 28, 2025, 3:59 PM
5.09
-1.17%
After-hours: Mar 28, 2025, 06:21 PM EDT
-3.56% (1D)
| Bid | 5.09 |
| Market Cap | 23.55M |
| Revenue (ttm) | 595.18K |
| Net Income (ttm) | -5.91M |
| EPS (ttm) | -15.53 |
| PE Ratio (ttm) | -0.33 |
| Forward PE | -6.31 |
| Analyst | Hold |
| Ask | 5.58 |
| Volume | 15,448 |
| Avg. Volume (20D) | 38,886 |
| Open | 5.27 |
| Previous Close | 5.34 |
| Day's Range | 5.07 - 5.43 |
| 52-Week Range | 2.71 - 11.39 |
| Beta | 0.50 |
About CARA
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of mod...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 31, 2014
Employees 10
Stock Exchange NASDAQ
Ticker Symbol CARA
Website https://www.caratherapeutics.com
Analyst Forecast
According to 3 analyst ratings, the average rating for CARA stock is "Hold." The 12-month stock price forecast is $12, which is an increase of 133.01% from the latest price.
Stock ForecastsNext Earnings Release
Cara Therapeutics Inc. is scheduled to release its earnings on Apr 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
9 months ago
-34.72%
Cara Therapeutics shares are trading lower after t...
Unlock content with
Pro Subscription
